Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.

Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Pharma: The year that was... - Views on News from Equitymaster
  • E-MAIL
  • A  A  A
  • May 29, 2007

    Pharma: The year that was...

    FY07 was a good year for the Indian pharma companies especially the domestic ones as revenues from exports picked up scale through acquisitions and better opportunity in terms of product launches in the global generics market. The performance of the MNC pharma companies, however, left a lot to be desired. In this article, we shall take a look at the overall performance of the pharma sector for FY07/CY06. We have included the 11 pharma companies under our research coverage for the purpose of the analysis.

    FY07: All round improvement
    (Rs m) FY06/CY05 FY07/CY06 Change
    Sales 195,114 271,922 139.4%
    EBDITA 34,318 60,925 177.5%
    EBDITA margin (%) 17.6% 22.4%  
    Net profit 29,642 44,844 151.3%
    Net profit margin (%) 15.2% 16.5%  
    * Includes the 11 pharma companies under our research coverage

    Both generics and CRAMS did well: FY07/CY06 has been a good year for domestic pharma companies focusing on the generics market. This is because this year represented the largest opportunity in terms of the number and the size of molecules losing patent expiry. Not only that, after a long time, domestic pharma companies were successful in garnering the 180-day exclusivity window for certain molecules allowing them to bolster their overall performance (case in point: Ranbaxy getting the exclusivity for 'Simvastatin 80 mg', Dr.Reddy's being the authorized generic for 'Simvastatin' and 'Finasteride' and also getting the exclusivity for 'Ondansetron' and Sun Pharma for 'Ultracet'). Having said that, the pricing pressure on these molecules, as expected, showed no signs of abating.

    FY07 also saw domestic pharma companies making a string of acquisitions in the generics space to expand geographically into Europe and the emerging markets in a bid to reduce dependence on the US market and attain critical scale. These acquisitions also largely contributed to the stellar performance reported by the domestic pharma companies. The year saw a flurry of activity on the CRAMS front as well with the acquisition of Avecia augmenting Nicholas Piramal's performance and the Roche facility in Mexico's lending a fillip to Dr.Reddy's operations.

    MNC pharma lagging behind: In comparison to their domestic counterparts, the performance of MNC pharma companies was subdued. MNC companies were slower in launching products from their parent's portfolio with Pfizer being the most aggressive of the lot (3 launches in the domestic market). Also, MNCs have to contend with a higher proportion of the turnover accounting for drugs under the DPCO cover (as compared to their domestic counterparts for whom this proportion is much lesser on account of their emphasis on exports). Going forward, launch of patented products into the country and the pricing of the same will be the key factors that will determine the fortunes of the MNC companies.

    Margin picture: Operating margins for the sector (i.e. the 11 companies under our coverage) improved by around 480 basis points. For the domestic companies the margin improvement has come about on account of the 180-day exclusivity period for products enabling them to earn higher margins, efforts to diversify the product mix and increased focus on branded and emerging markets. For MNC companies, margin improvement was largely attributed to the efforts to keep the overheads under control.

    Looking ahead...
    If one looks at the generics potential year wise, then CY06 did hold the strongest potential in term of patent expiries. Having said that, the global generics market continues to hold potential till CY10. Besides this, consolidation activity is expected to continue in the coming years as well as the pressure to gain scale builds up in wake of the increasing competition. Those companies having a balanced product portfolio and a wider geographical reach will be able to sustain growth in the highly competitive global generics market.

    CRAMS will continue to pick up pace as the pressure on global innovator companies to reduce costs continues to mount. In the domestic market, efforts by companies, both domestic and MNC, to keep the product portfolio fresh (largely through in-licensing), will be the key growth drivers. The government's stance on resolving the 'price control' issue will be the key development to watch out for. Thus, from a fundamental view while the domestic market, the global generics market and CRAMS hold strong potential going forward, we advise investors to adopt a stock specific approach while investing in the sector after giving due consideration to valuations.



    Equitymaster requests your view! Post a comment on "Pharma: The year that was...". Click here!


    More Views on News

    Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

    Aug 14, 2017

    A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

    Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

    Aug 14, 2017

    GST impact coupled with price erosion in US leads to lower profits for the quarter.

    Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

    Aug 8, 2017

    Profits plunge due to higher raw material costs.

    The Power of 5 Minutes (The 5 Minute Wrapup)

    Jun 16, 2017

    Here's what you can expect from The 5 Minute Wrapup in the coming months and years.

    Biocon: Lower Licensing Income Leads to Muted Growth for the Quarter (Quarterly Results Update - Detailed)

    Jun 23, 2017

    Net Profit lower due to exceptional items in the previous year.

    More Views on News

    Most Popular

    A 'Backdoor' to Multibaggers: It's Like Investing in Asian Paints Ten Years Ago(The 5 Minute Wrapup)

    Aug 10, 2017

    Don't miss these proxy bets on growing companies or in a few years you will be looking back with regret.

    The Most Profitable Investment in the History of the World(Vivek Kaul's Diary)

    Aug 8, 2017

    'Yes, it looks like a bubble. And, yes, it's like buying a lottery ticket. But there's something happening that has never happened before. It's an evolutionary leap in money itself.'

    Should You Invest In Bharat-22 ETF? Know Here...(Outside View)

    Aug 8, 2017

    Bharat-22 is one of the most diverse ETFs offered so far by the Government. Know here if you should invest...

    Signs of Life in the India VIX(Daily Profit Hunter)

    Aug 12, 2017

    The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.

    Bitcoin Continues Stellar Rise(Chart Of The Day)

    Aug 10, 2017

    Bitcoin hits an all-time high, is there more upside left?

    Copyright © Equitymaster Agora Research Private Limited. All rights reserved.
    Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

    LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA or Canada, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.

    SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

    Equitymaster Agora Research Private Limited. 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
    Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407

    Become A Smarter Investor In
    Just 5 Minutes

    Multibagger Stocks Guide 2017
    Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
    We will never sell or rent your email id.
    Please read our Terms


    Aug 21, 2017 03:37 PM